Dynamic biomarker signatures

Abstract

The present disclosure provides methods of identifying a subject with cancer that is non-responsive a treatment (e.g., immune checkpoint inhibitor monotherapy), wherein the cancer has an altered (e.g., increased or decreased) expression level of a panel of biomarkers, and methods of using the same to provide a combination therapy (e.g., a therapeutic targeting myeloid immune suppressive checkpoint (e.g., LAIR1) and an immune checkpoint inhibitor) to the subject with cancer.

Description

[0001]Attorney Docket: AHY-00725 DYNAMIC BIOMARKER SIGNATURES RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application Serial No.63 / 536,221 filed September 1, 2023. The entire contents of which are incorporated herein by this reference. BACKGROUND Although advances have been made in the types and number of cancer treatments, many patients fail to respond to such treatments. Clinical readouts to determine whether a patient is responsive to a treatment may take at least 6 months. During this time, the patient may suffer unnecessary financial, social, emotional, and physical hardship should they not respond. Further, awaiting determination of response to a cancer treatment delays the administration of combination therapies that the patient may benefit from to treat the cancer. SUMMARY In some aspects, the disclosure provides a method of providing a therapeutic targeting LAIR1 to treat cancer in the subject, comprising: (i) identifying the subject as likely to not respond to an immune checkpoint inhibitor monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a second panel of biomarkers in the biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor, thereby treating cancer in the subject. In some aspects, the disclosure provides a method of providing a therapeutic targeting LAIR1 to treat cancer in the subject, comprising: (i) identifying the subject as likely to not respond to an immune checkpoint inhibitor monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in the biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor, thereby treating cancer in the subject. In some aspects, the disclosure provides a method for identifying a subject that is non- responsive to an immune checkpoint inhibitor monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an immune checkpoint inhibitor monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in the biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and Attorney Docket: AHY-00725 (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor to the subject determined to have a response score. In some aspects, the disclosure provides a method for identifying a subject that is non- responsive to an immune checkpoint inhibitor monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an immune checkpoint inhibitor monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in the biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor to the subject determined to have a response score. In some embodiments, the immune checkpoint inhibitor monotherapy targets PD-1, PD- L1, CTLA4, LAG3, or any combination thereof. In some embodiments, the immune checkpoint Attorney Docket: AHY-00725 inhibitor monotherapy is an antibody. In some embodiments, the antibody is ipilimumab, nivolumab, relatlimab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, or dostarlimab. In some embodiments, the first panel of biomarkers comprises CA6, CDNF, MIA, MYOC, NEFL, and TCL1B. In some embodiments, the first panel of biomarkers comprises one or more of ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS. In some embodiments,the first panel of biomarkers comprises at least six of ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS. In some embodiments, the first panel of biomarkers comprises one or more of ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN. In some embodiments,the first panel of biomarkers comprises at least six of ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN. In some embodiments, the first panel of biomarkers comprises one or more of AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS. In some embodiments, the first panel of biomarkers comprises at least six of AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, Attorney Docket: AHY-00725 GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS. In some embodiments, the first panel of biomarkers comprises one or more of ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS. In some embodiments, the first panel of biomarkers comprises at least six of ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS. In some embodiments, the second panel of biomarkers comprises at least four of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1. In some embodiments, the second panel of biomarkers comprises 2-13 biomarkers of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1. In some embodiments, the second panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1. In some embodiments, the second panel of biomarkers further comprises LILRB4 and VSIG4. In some embodiments, the first panel of biomarkers comprises proteins. In some embodiments, (i)(a) comprises detecting the first panel of biomarkers in the biological sample by enzyme-linked immunosorbent assay (ELISA) or proximity extension assay (PEA). In some embodiments, the second panel of biomarkers comprises proteins. In some embodiments, (ii)(a) comprises detecting the second panel of biomarkers in the biological sample by enzyme-linked immunosorbent assay (ELISA) or proximity extension assay (PEA). In some embodiments, the first panel of biomarkers comprises nucleic acid molecules. In some embodiments, (i)(a) comprises detecting the first panel of biomarkers in the biological sample by a nucleic acid hybridization assay, a nucleic acid amplification assay, or sequencing. In some embodiments, the second panel of biomarkers comprises nucleic acid molecules. In some embodiments, (ii)(a) comprises detecting the second panel of biomarkers in the biological sample by a nucleic acid hybridization assay, a nucleic acid amplification assay, or sequencing. Attorney Docket: AHY-00725 In some embodiments, the therapeutic targeting LAIR1 is an antibody, a nucleic acid molecule, a protein therapeutic, a cell therapy, or a small molecule. In some embodiments, the therapeutic targeting LAIR1 is an antibody. In some embodiments, the biological sample is a blood sample, a serum sample, or a plasma sample. In some embodiments, the biological sample is a plasma sample. In some embodiments, the at least one subsequent time point is before clinical readout. In some embodiments, the first and second panel of biomarkers is determined from at least two subsequent time points. In some embodiments, the amount or level of the first panel of biomarkers is increased between the first time point and the at least one subsequent time point. In some embodiments, the increased amount or level of the first panel of biomarkers between the first time point and the at least one subsequent time point is statistically significant. In some embodiments, the amount or level of the second panel of biomarkers is increased between the first time point and the at least one subsequent time point. In some embodiments, the increased amount or level of the first panel of biomarkers between the first time point and the at least one subsequent time point is statistically significant. In some embodiments, the amount or level of the panel of biomarkers is increased by at least 1.5-fold, 2-fold, 5-fold, 10-fold, 15-fold, or 20- fold. In some embodiments, the amount or level of the panel of biomarkers is increased by at least 1.5-fold. In some embodiments, the diagnostic accuracy is at least 0.8. In some embodiments, the non-response score indicated the subject will not respond to the immune checkpoint inhibitory therapy. In some embodiments, the therapeutic targeting LAIR1 improves the subject’s response to the immune checkpoint inhibitor monotherapy. In some aspects, the disclosure provides a kit suitable for performing the methods of some or any of the foregoing or related embodiments, comprising (i) one or more reagents for detecting the amount or level of the first panel of biomarkers, and (ii) instructions for detecting the amount or level of the first panel of biomarkers in a biological sample from a subject obtained from two or more different time points. In some embodiments, the kit comprises (iii) one or more reagents for detecting the amount or level of the second panel of biomarkers, and (iv) instructions for detecting the amount or level of the second panel of biomarkers in a biological sample from a subject obtained from two or more different time points. Attorney Docket: AHY-00725 In some aspects, the disclosure provides a kit suitable for performing the methods of some or any of the foregoing or related embodiments, comprising (i) one or more reagents for detecting the amount or level of the second panel of biomarkers, and (ii) instructions for detecting the amount or level of the second panel of biomarkers in a biological sample from a subject obtained from two or more different time points. In some embodiments, the kit comprises (iii) one or more reagents for detecting the amount or level of the first panel of biomarkers, and (iv) instructions for detecting the amount or level of the first panel of biomarkers in a biological sample from a subject obtained from two or more different time points. In some embodiments, the kit comprises instructions for identifying the subject as not likely to respond to an immune checkpoint inhibitor monotherapy. In some embodiments, the kit comprises instructions for identifying the subject as likely to respond to a combination therapy of a therapeutic targeting LAIR1. In some embodiments, the biological sample is a blood sample, a serum sample, or a plasma sample. In some aspects, the disclosure provides a method for identifying a subject that is non- responsive or predicted to be non-responsive to an immune checkpoint inhibitor monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject at two or more different time points, wherein the first time point is prior to administration of the immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor to the subject determined to have a response score. Attorney Docket: AHY-00725 In some embodiments, the therapeutic targeting LAIR1 is an antibody, a nucleic acid molecule, a protein therapeutic, a cell therapy, or a small molecule. In some embodiments, the therapeutic targeting LAIR1 is an antibody. In some embodiments, the panel of biomarkers comprises at least four of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1. In some embodiments, the panel of biomarkers comprises 2-13 biomarkers of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1. In some embodiments, the panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1. In some embodiments, the panel of biomarkers further comprises LILRB4 and VSIG4. In some aspects, the disclosure provides a method for identifying a subject for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified as a non-responder or predicted to be a non-responder to an immune checkpoint inhibitor monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the immune checkpoint inhibitor; and (iv) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the immune checkpoint inhibitor to the subject determined to have the response score. In some embodiments, the panel of biomarkers comprises at least four of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8. In some embodiments, the panel of biomarkers comprises 2-12 of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8. In some embodiments, the panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and Attorney Docket: AHY-00725 MMP8. In some embodiments, the panel of biomarkers further comprises at least one of LAIR1, LILRB4 and VSIG4. In some embodiments, the panel of biomarkers further comprises LAIR1, LILRB4 and VSIG4. In some embodiments, the therapeutic targeting a myeloid immune suppressive checkpoint is an antibody, a nucleic acid molecule, a protein therapeutic, a cell therapy, or a small molecule. In some embodiments, the immune checkpoint inhibitor targets PD-1, PD-L1, CTLA4, LAG3, or any combination thereof. In some embodiments, the immune checkpoint inhibitor is an antibody. In some embodiments, the antibody is ipilimumab, nivolumab, relatlimab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, or dostarlimab. In some embodiments, the panel of biomarkers comprises proteins. In some embodiments, determining the amount or level of a panel of biomarkers comprises detecting the panel of biomarkers in the biological sample by enzyme-linked immunosorbent assay (ELISA) or proximity extension assay (PEA). In some embodiments, the panel of biomarkers comprises nucleic acid molecules. In some embodiments, determining the amount or level of a panel of biomarkers comprises detecting the panel of biomarkers in the biological sample by a nucleic acid hybridization assay, a nucleic acid amplification assay or sequencing. In some embodiments, the biological sample is a blood sample, a serum sample, or a plasma sample. In some embodiments, the biological sample is a plasma sample. In some embodiments, the at least one subsequent time point is before clinical readout. In some embodiments, the panel of biomarkers is determined from at least two subsequent time points. In some embodiments, the amount or level of the panel of biomarkers is increased between the first time point and the at least one subsequent time point. In some embodiments, the increased amount or level of the panel of biomarkers between the first time point and the at least one subsequent time point is statistically significant. In some embodiments, the response score indicates the subject will respond to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the immune checkpoint inhibitor. In some aspects, the disclosure provides a kit suitable for performing the method of some or any of the foregoing or related embodiments, comprising (i) one or more reagents for detecting the amount or level of the panel of biomarkers, and (ii) instructions for detecting the Attorney Docket: AHY-00725 amount or level of the panel of biomarkers in a biological sample from a subject obtained from two or more different time points. In some embodiments, the instructions comprise steps for identifying the subject as likely to respond to a combination therapy of a therapeutic targeting LAIR1 or a therapeutic targeting a myeloid immune suppressive checkpoint and an immune checkpoint inhibitor. In some embodiments, the biological sample is a blood sample, a serum sample, or a plasma sample. BRIEF DESCRIPTION OF THE DRAWINGS FIGs.1A-1B shows protein signatures of non-responders (NR) at baseline (pre-treatment with one or more immune checkpoint inhibitors (anti-PD-1 or a combination of anti-PD-1 with anti-CTLA-4)). FIG.1A provides a graph showing an ROC curve plotting sensitivity versus specificity for predicting NR. AUC = 0.59. FIG. 1B provides a graph showing the plasma proteins identified using Olink proteomic analysis that comprise the predictive model rank ordered based on their selection frequency in cross validation of the predictive model. ROC = receiver operating characteristic; AUC = area under the ROC curve. FIGs.2A-2B shows dynamic protein signatures of non-responders (NR) at baseline and 6 weeks post-treatment initiation with one or more immune checkpoint inhibitors (anti-PD-1 or a combination of anti-PD-1 with anti-CTLA-4). FIG.2A provides a graph showing a ROC curve plotting sensitivity versus specificity for predicting NR. AUC = 0.71. FIG. 2B provides a graph showing the plasma proteins identified using Olink proteomic analysis that comprise the predictive model rank ordered based on their selection frequency in cross validation of the predictive model. ROC = receiver operating characteristic; AUC = area under the ROC curve. FIGs.3A-3B shows dynamic protein signatures of non-responders (NR) at baseline and 6 months post-treatment initiation with one or more immune checkpoint inhibitors (anti-PD-1 or a combination of anti-PD-1 with anti-CTLA-4). FIG.3A provides a graph showing a ROC curve plotting sensitivity versus specificity for predicting NR. AUC = 0.76. FIG. 3B provides a graph showing the plasma proteins identified using Olink proteomic analysis that comprise the predictive model rank ordered based on their selection frequency in cross validation of the predictive model. ROC = receiver operating characteristic; AUC = area under the ROC curve. FIGs.4A-4B shows dynamic protein signatures of non-responders (NR) at baseline, 6 weeks, and 6-months post-treatment initiation with one or more immune checkpoint inhibitors Attorney Docket: AHY-00725 (anti-PD-1 or a combination of anti-PD-1 with anti-CTLA-4). FIG. 4A provides a graph showing a ROC curve plotting sensitivity versus specificity for predicting NR. AUC = 0.80. FIG.4B provides a graph showing the plasma proteins identified using Olink proteomic analysis that comprise the predictive model rank ordered based on their selection frequency in cross validation of the predictive model. ROC = receiver operating characteristic; AUC = area under the ROC curve. FIGs.5A-5B shows dynamic protein signatures of non-responders (NR) at 6 weeks and 6-months post-treatment initiation with one or more immune checkpoint inhibitors (anti-PD-1 or a combination of anti-PD-1 with anti-CTLA-4). FIG. 5A provides a graph showing a ROC curve plotting sensitivity versus specificity for predicting NR. AUC = 0.74. FIG. 5B provides a graph showing the plasma proteins identified using Olink proteomic analysis that comprise the predictive model rank ordered based on their selection frequency in cross validation of the predictive model. ROC = receiver operating characteristic; AUC = area under the ROC curve. FIGs.6A-6B show gene set enrichment analyses (GSEA) of plasma protein samples from patients identified as responders and non-responders to immune checkpoint inhibitor treatment, where the statistically significant differences between the patient groups are shown at baseline (FIG. 6A) or at baseline, 6-weeks and 6-months after treatment (FIG.6B). Gene set enrichment is depicted by adjusted p-value (p.adjust) and count number. NES = normalized enrichment score. FIG.7 shows the change in relative expression of LAIR1 across 6 months in patients identified as responders or non-responders to one or more immune checkpoint inhibitor treatment. DETAILED DESCRIPTION Overview In some aspects, the disclosure is based, at least in part, on the discovery of a dynamic signature for predicting a subject with cancer is not likely to respond to an immune checkpoint inhibitor (ICI) monotherapy with a diagnostic accuracy of at least 0.7. As demonstrated herein, biological samples from a population of subjects with cancer and treated with ICI monotherapy were analyzed at different time points pre- and post-treatment with ICI monotherapy. Subjects that were identified by clinical read-out as non-responders were found to express a panel of Attorney Docket: AHY-00725 biomarkers that changed over time. As shown herein, the panel of biomarkers had a higher predictive value of non-response to ICI monotherapy when evaluated at multiple time points compared to evaluation at a single time point. Specifically, when the panel of biomarkers was evaluated at baseline (i.e., pre-treatment), 6-weeks post treatment and 6-months post treatment, an AUC of 0.80 was identified. In contrast, evaluating the panel of biomarkers at only baseline provided an AUC of 0.59. Accordingly, without wishing to be bound by theory, the amount or level of the panel of biomarkers determined over time predicts whether a subject will respond to ICI monotherapy. It is believed the dynamic signature described herein predicts whether a subject is not likely to respond to ICI monotherapy before clinical readout, thus providing improved patient care. In further aspects, the disclosure is based, at least in part, on the discovery of a dynamic myeloid signature for predicting whether a subject with cancer identified or predicted as non- responsive to an ICI monotherapy is likely to respond to a therapeutic targeted to a myeloid immune suppressive checkpoint, alone or in combination with the ICI. As demonstrated herein, differentially regulated proteins between non-responders and responders were identified and evaluated using Gene Set Enrichment Analysis (GSEA) with the Gene Ontology (GO) database and were annotated to have biological processes related to myeloid biology. Specifically, the analysis annotated regulation of macrophage activation, positive regulation of macrophage activation, macrophage activation, and myeloid leukocyte activation. Based on this analysis, a panel of biomarkers were identified as changing over time in the non-responders by comparison to responders. It was further demonstrated that myeloid immune suppressive checkpoint LAIR1 was identified as increasing over time in patients non-responsive to ICI monotherapy. Accordingly, without wishing to be bound by theory, the panel of biomarkers determined over time is useful to identify a subject non-responsive to ICI monotherapy or predicted to be non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint (e.g., LAIR1), alone or in combination with an ICI. It is believed the dynamic myeloid signature described herein predicts whether a subject identified or predicted as non-responsive to ICI monotherapy is likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint (e.g., LAIR1), alone or in combination with an ICI. In some aspects, the present disclosure provides methods for identifying a subject with cancer likely to not respond to an immune checkpoint inhibitor (ICI) monotherapy. In some aspects, the disclosure provides methods for providing a therapeutic targeting LAIR1 to a subject Attorney Docket: AHY-00725 with cancer to treat cancer in the subject. In some embodiments, the panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B. In some embodiments, the methods described herein comprise comparing the amount or level of the panel of biomarkers from the two or more time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that a subject is not likely to respond to the immune checkpoint inhibitor monotherapy. In some embodiments, the methods described herein comprise administering a therapeutic targeting LAIR1 to a subject with cancer determined to have a non-response score, thereby treating cancer in the subject. In some aspects, the present disclosure provides methods for identifying a subject with cancer that is non-responsive to immune checkpoint inhibitor (ICI) monotherapy who is likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint (e.g., LAIR1). In some aspects, the disclosure provides methods for providing a therapeutic targeting a myeloid immune suppressive checkpoint (e.g., LAIR1) to a subject with cancer to treat cancer in the subject. In some aspects, the present disclosure provides methods for identifying a subject with cancer that is non-responsive to immune checkpoint inhibitor (ICI) monotherapy who is likely to respond to a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint (e.g., LAIR1) and an ICI. In some aspects, the disclosure provides methods for providing a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint (e.g., LAIR1) and an ICI to a subject with cancer to treat cancer in the subject. In some embodiments, the methods described herein comprise providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points. In some embodiments, the biomarkers are blood-based biomarkers. In some embodiments, the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and the one or more subsequent time points is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor. In some embodiments, the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the methods described herein comprise comparing the amount or level of the panel of biomarkers from the two or more time points to determine a response score, wherein the response score indicates if subject is likely to respond to a therapeutic targeting a myeloid Attorney Docket: AHY-00725 immune suppressive checkpoint (e.g., LAIR1), alone or in combination with an immune checkpoint inhibitor. In some embodiments, the myeloid suppressive therapeutic targets LAIR1. Dynamic Biomarker Signatures In some aspects, the disclosure provides dynamic biomarker signatures. As used herein, a “dynamic signature” refers to a panel of one or more biomarkers that change levels or amounts over time from pre-treatment to post-treatment with a therapeutic (e.g., an immune checkpoint inhibitor monotherapy). A dynamic signature can be used, for example, to predict response to additional treatments in non-responders to standard of care (SOC), or to predict biological mechanisms (e.g., myeloid biology) and specific target(s) (e.g., LAIR1) that are responsible for the lack of response to SOC. As used herein, the term “responsiveness” refers to the degree to which a diseased tissue (e.g., a tumor) in a subject undergoes a desirable therapeutic change upon exposure to a therapeutic intervention (e.g., ICI monotherapy). In some embodiments, the dynamic signature is based on the amount or level of the panel of biomarkers determined at two more time points. In some embodiments, the two or more time points includes a time point pre-treatment and at least one subsequent time point post-treatment. In some embodiments, the dynamic signature is based on an amount or level of a panel of biomarkers determined from two or more time points. In some embodiments, the disclosure provides a panel of biomarkers having altered (e.g., increased or decreased) expression level and / or activity in one or more subjects having cancer and treated with an ICI monotherapy. As used herein, a “biomarker” refers to a gene, or a transcriptional or translational product thereof, whose expression level and / or activity can be detected in a biological sample obtained from a subject having a disease or disorder (e.g., cancer), wherein an altered (e.g., increased or decreased) expression level and / or activity of the biomarker functions as an indicator (e.g., diagnostic, predictive, and / or prognostic indicator). In some embodiments, the biomarker is a predictive indicator, wherein an altered expression level and / or activity of the biomarker indicates responsiveness of the disease to a particular therapeutic intervention. In some embodiments, the biomarker is a prognostic indicator, wherein an altered expression level and / or activity of the biomarker indicates an outcome of the disease or disease progression regardless of therapeutic intervention. In some embodiments, the biomarker is a predictive or Attorney Docket: AHY-00725 prognostic indicator when the expression level and / or activity of the biomarker is determined at two or more time points. In some embodiments, the amount or level of the biomarker is compared to a reference sample. As used herein, a “reference sample,” “reference cell”, “reference tissue”, “control sample”, “control cell,” or “control tissue” each refer to a sample, cell, tissue, standard, or level that is used for comparison to establish whether the amount or level of the biomarker in a subject is altered. In some embodiments, the reference is the amount or level of the biomarker in the subject before administration of a therapeutic intervention (e.g., ICI monotherapy). In some embodiments, the reference is a pre-determined amount or level of the biomarker. Dynamic Non-Responder Signature In some aspects, the present disclosure provides a dynamic signature for identifying a subject with cancer not likely to respond to an immune checkpoint inhibitor monotherapy. In some embodiments, the dynamic signature comprises a panel of biomarkers analyzed at more than one time point. Panel of Biomarkers In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS. In some embodiments, the panel of biomarkers comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, or 68 biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, Attorney Docket: AHY-00725 MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS. In some embodiments, the panel of biomarkers comprises 2-30, 5-25, 10-20, 15-30, 20- 40, 30-60, 30-50, or 40-68 biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS. In some embodiments, the panel of biomarkers comprises ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS. In some embodiments, the panel of biomarkers comprises ADAM22. In some embodiments, the panel of biomarkers comprises ADAMTS8. In some embodiments, the panel of biomarkers comprises AMTS8. In some embodiments, the panel of biomarkers comprises ANGPT2. In some embodiments, the panel of biomarkers comprises is AOC1. In some embodiments, the panel of biomarkers comprises is BCL2L11. In some embodiments, the panel of biomarkers comprises is BMP4. In some embodiments, the panel of biomarkers comprises is BRK1. In some embodiments, the panel of biomarkers comprises CA6. In some embodiments, a biomarker of the disclosure is CCL13. In some embodiments, the panel of biomarkers comprises CCL25. In some embodiments, the panel of biomarkers comprises CD14. In some embodiments, the panel of biomarkers comprises CD34. In some embodiments, the panel of biomarkers comprises CDH17. In some embodiments, the panel of biomarkers comprises is CDNF. In some embodiments, the panel of biomarkers comprises CERT. In some embodiments, the panel of biomarkers comprises CES3. In some embodiments, the panel of biomarkers comprises CLEC4A. In some embodiments, a biomarker of the disclosure is CPVL. In some embodiments, Attorney Docket: AHY-00725 the panel of biomarkers comprises CSF3. In some embodiments, the panel of biomarkers comprises CTSF. In some embodiments, the panel of biomarkers comprises CTSL. In some embodiments, the panel of biomarkers comprises DKK4. In some embodiments, the panel of biomarkers comprises ECE1. In some embodiments, the panel of biomarkers comprises ENG. In some embodiments, the panel of biomarkers comprises FBP1. In some embodiments, the panel of biomarkers comprises FRZB. In some embodiments, the panel of biomarkers comprises GBP2. In some embodiments, the panel of biomarkers comprises GFBP2. In some embodiments, the panel of biomarkers comprises GLT8D2. In some embodiments, the panel of biomarkers comprises GPR37. In some embodiments, the panel of biomarkers comprises HGF. In some embodiments, the panel of biomarkers comprises HMBS. In some embodiments, the panel of biomarkers comprises IGFBP2. In some embodiments, the panel of biomarkers comprises IL5. In some embodiments, a biomarker of the disclosure is IL6. In some embodiments, the panel of biomarkers comprises ITGB6. In some embodiments, the panel of biomarkers comprises ITM2A. In some embodiments the panel of biomarkers comprises KRT5. In some embodiments, the panel of biomarkers comprises LILRB4. In some embodiments, the panel of biomarkers comprises MIA. In some embodiments, the panel of biomarkers comprises MMP13. In some embodiments, the panel of biomarkers comprises MMP3. In some embodiments, the panel of biomarkers comprises MMP8. In some embodiments, the panel of biomarkers comprises MYOC. In some embodiments, the panel of biomarkers comprises NEFL. In some embodiments, the panel of biomarkers comprises NID1. In some embodiments the panel of biomarkers comprises NOS3. In some embodiments, the panel of biomarkers comprises NRP1. In some embodiments, the panel of biomarkers comprises PAEP. In some embodiments, the panel of biomarkers comprises PAPPA. In some embodiments, the panel of biomarkers comprises PRTG. In some embodiments, the panel of biomarkers comprises PSPN. In some embodiments, the panel of biomarkers comprises PTGDS. In some embodiments, the panel of biomarkers comprises SFTPD. In some embodiments, the panel of biomarkers comprises SMOC1. In some embodiments, the panel of biomarkers comprises TCL1A. In some embodiments, the panel of biomarkers comprises TCL1B. In some embodiments, the panel of biomarkers comprises TCN2. In some embodiments, the panel of biomarkers comprises TDGF1. In some embodiments, the panel of biomarkers comprises TFPI. In some embodiments, the panel of biomarkers comprises TGREM2. In some embodiments, the panel of biomarkers comprises TINAGL1. In some embodiments, the panel of biomarkers comprises TNC. In some embodiments, the panel of Attorney Docket: AHY-00725 biomarkers comprises TNFRSF10B. In some embodiments, the panel of biomarkers comprises TNFSF14. In some embodiments, the panel of biomarkers comprises VASN. In some embodiments, the panel of biomarkers comprises WARS. In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B. In some embodiments, the panel of biomarkers comprises 1, 2, 3, 4, 5, or 6 biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B. In some embodiments, the panel of biomarkers comprises 2-5, 2-6, or 3-6 biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B. In some embodiments, the panel of biomarkers comprises CA6, CDNF, MIA, MYOC, NEFL, and TCL1B. In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN. In some embodiments, the panel of biomarkers comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN. In some embodiments, the panel of biomarkers comprises 2-30, 5-25, 10-20, 15-30, 20- 31, or 10-31 biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN. In some embodiments, the panel of biomarkers comprises ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN. In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, Attorney Docket: AHY-00725 ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS. In some embodiments, the panel of biomarkers comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or 38 biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS. In some embodiments, the panel of biomarkers comprises 2-30, 5-25, 10-20, 15-30, 20- 38, 30-38, or 10-30 biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS. In some embodiments, the panel of biomarkers comprises AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS. In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS. In some embodiments, the panel of biomarkers comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34 biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS. In some embodiments, the panel of biomarkers comprises 2-30, 5-25, 10-20, 15-30, 20- 30, 25-34 biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, Attorney Docket: AHY-00725 ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS. In some embodiments, the panel of biomarkers comprises ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS. Dynamic Myeloid Signature In some aspects, the present disclosure provides a dynamic signature for identifying a subject with cancer that is non-responsive to an immune checkpoint inhibitor monotherapy that would benefit from additional immune suppression therapy. In some embodiments, the dynamic signature comprises a panel of biomarkers analyzed at more than one time point. Panel of Biomarkers In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises one or more biomarkers selected from: LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, biomarkers selected from: AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 biomarkers selected from: LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises 2-12, 5-12, 10-12, or 2-10 biomarkers selected from: AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises 2-13, 5-13, 10- Attorney Docket: AHY-00725 13, or 2-10 biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises 2-15, 5-15, 10-15, or 2-10 biomarkers selected from: LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the panel of biomarkers comprises LILRB4. In some embodiments, the panel of biomarkers comprises LAIR1. In some embodiments, the panel of biomarkers comprises VSIG4. In some embodiments, the panel of biomarkers comprises AZU1. In some embodiments, the panel of biomarkers comprises CCL3. In some embodiments, the panel of biomarkers comprises CST7. In some embodiments, the panel of biomarkers comprises HAVCR2. In some embodiments, the panel of biomarkers comprises IFNG. In some embodiments, the panel of biomarkers comprises IL10. In some embodiments, the panel of biomarkers comprises IL1RL1. In some embodiments, the panel of biomarkers comprises IL4R. In some embodiments, the panel of biomarkers comprises IL6. In some embodiments, the panel of biomarkers comprises LBP. In some embodiments, the panel of biomarkers comprises MIF. In some embodiments, the panel of biomarkers comprises MMP8. Detection of Biomarkers In some aspects, the disclosure provides methods of detecting one or more biomarkers in a biological sample from a subject. In some embodiments, a biomarker is a protein. In some embodiments, a biomarker is a nucleic acid molecule encoding a protein (e.g., DNA or RNA). In some embodiments, the panel of biomarkers comprises one or more proteins. In some embodiments, the panel of biomarkers comprises one or more nucleic acid molecules. In some embodiments, the panel of biomarkers comprises a combination of proteins and nucleic acid molecules. Methods for detecting proteins and nucleic acid molecules encoding proteins are known to those of skill in the art and described herein. Attorney Docket: AHY-00725 Detection of Protein In some embodiments, the present disclosure provides methods for detecting protein in a biological sample. Methods for detecting proteins and fragments thereof are known to those of skill in the art. Exemplary methods include enzyme-linked immunosorbent assay (ELISA), western blot, proximity extension assay (PEA), mass-spectrometry and immunobead-based formats. In some embodiments, wherein more than one protein biomarker is detected, the same protein detection method is utilized. In some embodiments, wherein more than one protein biomarker is detected, different protein detection methods are utilized. For example, in some embodiments, a first protein biomarker is detected by a first ELISA and a second protein biomarker is detected by a second ELISA. In some embodiments, wherein more than one protein biomarker is detected, the proteins are detected simultaneously. In some embodiments, wherein more than one protein biomarker is detected, the proteins are detected in a multiplex format. For example, in some embodiments, first and second protein biomarkers are detected in the same assay. In some embodiments, one or more protein biomarkers are detected with an antibody. Antibodies include any type of antibody, including antibodies that specifically bind unmodified proteins, glycosylated protein variants, or other post-translationally modified proteins. In some embodiments, these antibodies are used in protein detection methods. Methods for generating antibodies suitable for binding a protein of interest are known those of skill in the art and described herein. In some embodiments, antibodies for detecting one or more protein biomarkers are commercially available. Exemplary immunodetection methods include radioimmunoassay (RIA), ELISA, fluoroimmunoassay, immunoradiometric assay, immunobead-based formats, chemiluminescent assay, and bioluminescent assay. In some embodiments, a method suitable for detecting the presence or amount of one or more protein biomarkers is a proximity extension assay (PEA). In this assay, a pair of antibodies linked to unique oligonucleotides (proximity probes) binds to a protein target. Based on this binding, the probes come in close proximity and hybridize to each other. The method further comprises adding a DNA polymerase to extend the hybridizing oligo and create a DNA amplicon Attorney Docket: AHY-00725 that can subsequently be detected and quantified by quantitative real-time PCR or next generation sequence (NGS). In some embodiments, a method suitable for detecting the presence or amount of one or more protein biomarkers is an ELISA. In this method, one or more antibodies specific for the one or more protein biomarkers are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate. Then, a test composition suspected of containing the one or more protein biomarkers, such as a diluted clinical sample, is added to the wells. After binding and / or washing to remove non-specifically bound immune complexes, the bound protein biomarker may be detected. Detection can be achieved by contacting the sample with an agent, such as a secondary antibody, that is linked to a detectable label. This type of ELISA is a "sandwich ELISA". Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating and binding, washing to remove non-specifically bound species, and detecting the bound immune complexes. These are described below. In some embodiments, the method for detecting one or more protein biomarkers is an immunobead-based assay (e.g., Luminex). In some embodiments, the method for detecting one or more protein biomarkers is multiplexed immunobead-based assay. In some embodiments, an antibody targeting the one or more protein biomarker is conjugated to a bead. In some embodiments, upon binding of the antibody to the one or more protein biomarkers, the bead detected using a method known to those of skill in the art or described herein. Detection of Nucleic Acids In some embodiments, the present disclosure provides methods for detecting nucleic acid molecules in a biological sample. Methods for detecting nucleic acid molecules are known to those of skill in the art, including but not limited to: nucleic acid sequencing; nucleic acid hybridization; and, nucleic acid amplification. In some embodiments, nucleic acid sequencing methods are utilized (e.g., for detection of amplified nucleic acids). In some embodiments, the technology provided herein finds use in a Second Generation (a.k.a. Next Generation or Next-Gen), Third Generation (a.k.a. Next-Next- Gen), or Fourth Generation (a.k.a. N3-Gen) sequencing technology including, but not limited to, pyrosequencing, sequencing-by-ligation, single molecule sequencing, sequence-by-synthesis Attorney Docket: AHY-00725 (SBS), semiconductor sequencing, massive parallel clonal, massive parallel single molecule SBS, massive parallel single molecule real-time, massive parallel single molecule real-time nanopore technology, etc. Morozova and Marra provide a review of some such technologies in Genomics, 92: 255 (2008), herein incorporated by reference in its entirety. Those of skill in the art will recognize that because RNA is less stable in the cell and more prone to nuclease attack experimentally RNA can be reverse transcribed to DNA before sequencing. A number of DNA sequencing techniques are suitable, including fluorescence-based sequencing methodologies (See, e.g., Birren et al., Genome Analysis: Analyzing DNA, 1, Cold Spring Harbor, N.Y.; herein incorporated by reference in its entirety). In some embodiments, automated sequencing techniques understood in that art are utilized. Illustrative non-limiting examples of nucleic acid hybridization techniques include, but are not limited to, in situ hybridization (ISH), microarray, and Southern or Northern blot. In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA or RNA strand as a probe to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough, the entire tissue (whole mount ISH). DNA ISH can be used to determine the structure of chromosomes. RNA ISH can be used to measure and localize mRNAs and other transcripts (e.g., cancer markers) within tissue sections or whole mounts. Sample cells and tissues can be treated to fix the target transcripts in place and to increase access of the probe. The probe hybridizes to the target sequence at elevated temperature, and then the excess probe is washed away. The probe that was labeled with either radio-, fluorescent- or antigen-labeled bases is localized and quantitated in the tissue using either autoradiography, fluorescence microscopy or immunohistochemistry, respectively. ISH can also use two or more probes, labeled with radioactivity or the other non-radioactive labels, to simultaneously detect two or more transcripts. In some embodiments, the one or more biomarkers are detected by conducting one or more hybridization reactions. In some embodiments, the one or more hybridization reactions comprise one or more hybridization arrays, hybridization reactions, hybridization chain reactions, isothermal hybridization reactions, nucleic acid hybridization reactions, or a combination thereof. In some embodiments, the one or more hybridization arrays comprise hybridization array genotyping, hybridization array proportional sensing, DNA hybridization arrays, macroarrays, microarrays, high-density oligonucleotide arrays, genomic hybridization arrays, comparative hybridization arrays, or a combination thereof. Attorney Docket: AHY-00725 In some embodiments, a microarray is used to determine the amount or level of the one or more biomarkers described herein. Microarrays include but are not limited to: DNA microarrays (e.g., cDNA microarrays and oligonucleotide microarrays); protein microarrays; tissue microarrays; transfection or cell microarrays; chemical compound microarrays; and, antibody microarrays. A DNA microarray, commonly known as gene chip, DNA chip, or biochip, is a collection of microscopic DNA spots attached to a solid surface (e.g., glass, plastic or silicon chip) forming an array for the purpose of expression profiling or monitoring expression levels for thousands of genes simultaneously. The affixed DNA segments are known as probes, thousands of which can be used in a single DNA microarray. Microarrays can be fabricated using a variety of technologies, including but not limiting: printing with fine-pointed pins onto glass slides; photolithography using pre-made masks; photolithography using dynamic micromirror devices; ink-jet printing; or, electrochemistry on microelectrode arrays. Biological Samples The methods described herein are useful for detecting a panel of biomarkers at one or more time points in a biological sample obtained from a subject. Exemplary biological samples include, but are not limited to, plasma, urine, saliva, whole blood, dried blood spot, serum, dried serum spot, stool, and / or hair. In some embodiments, the biological sample is derived from blood. In some embodiments, the biological sample is serum. In some embodiments, the biological is plasma. In some embodiments, the biological sample is whole blood, serum or plasma. In some embodiments, a processed biological sample, e.g., blood plasma or serum, is frozen for transport and / or long-term storage. In some embodiments, the same type of biological sample is obtained at two or more distinct time points. In some embodiments, different biological samples are obtained at two or more distinct time points. For example, a blood sample is obtained at a first time point, and a urine sample is obtained at a second time point. In contrast, a first blood sample is obtained from a first time point, and a second blood sample is obtained from a second time point. In some embodiments, the two or more biological samples obtained from the same subject are processed simultaneously. In some embodiments, the two or more biological samples obtained from the same subject are processed at different time points. In some embodiments, the panel of biomarkers is detected in the two or more biological samples at the same time. In some Attorney Docket: AHY-00725 embodiments, the panel of biomarkers is detected in the two or more biological samples at different times. In some embodiments, one or more biomarkers are detected in a biological sample obtained from a subject, e.g., plasma, urine, saliva, whole blood, dried blood spot, serum, dried serum spot, stool, and / or hair. In some embodiments, one or more biomarkers are detected in plasma. In some embodiments, one or more biomarkers are detected in urine. In some embodiments, one or more biomarkers are detected in saliva. In some embodiments, one or more biomarkers are detected in whole blood. In some embodiments, one or more biomarkers are detected in dried blood spot. In some embodiments, one or more biomarkers are detected in serum. In some embodiments, one or more biomarkers are detected in dried serum spot. In some embodiments, one or more biomarkers are detected in stool. In some embodiments, one or more biomarkers are detected in hair. In some embodiments, the biological sample is processed to allow for detecting of the biomarker. In some embodiments, a biological sample is processed in a manner consistent with methods for detecting protein or nucleic acids. In some embodiments, a sample is processed to isolate the proteins for detection. Methods for isolating proteins are known to those of skill in the art. In some embodiments, a sample is processed to isolate nucleic acid molecules for detection. Methods for isolating nucleic acid molecules are known to those of skill in the art. Determining Panel of Biomarkers and Dynamic Signatures In some embodiments, the disclosure provides methods of determining a dynamic signature suitable for use in the methods disclosed herein. In some embodiments, the dynamic signature is based on a panel of biomarkers described herein. In some embodiments, the panel of biomarkers for the dynamic signature is identified by determining the amount or level of one or more biomarkers from one or more biological samples from a subject. In some embodiments, the amount or level of one or more biomarkers is determined at two or more time points. In some embodiments, the amount or level of one or more biomarkers is determined before a subject receives a treatment (e.g., ICI monotherapy). In some embodiments, the amount or level of one or more biomarkers is determined after a subject receives a treatment (e.g., ICI monotherapy). In some embodiments, the amount or level of one or more biomarkers is determined before a subject receives a treatment and after the subject receives the treatment. Attorney Docket: AHY-00725 In some embodiments, biomarkers are ranked by their frequency of identification. For example, in some embodiments, biomarkers are ranked by their frequency of identification from repeats of cross-validation. In some embodiments, a biomarker has a frequency of identification from 0% to 100%. In some embodiments, a biomarker has a frequency of identification from about 0%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%, 78%, 80%, 82%, 84%, 86%, 88%, 90%, 92%, 94%, 96%, 98%, up to at most 100%. In some embodiments, a biomarker has a frequency of identification from about 1% to about 10%, about 5% to about 20%, about 10% to about 30%, about 20% to about 40%, about 30% to about 50%, about 40% to about 100%, about 50% to about 90%, about 15% to about 40%, about 20% to about 50%, about 10% to about 45%, or about 25% to about 50%. In some embodiments, a biomarker has a frequency of identification of about 25%. In some embodiments, the panel of biomarkers and the dynamic signature is identified using a computational approach. In some embodiments, a predictive algorithm is applied to a dataset compiled from screens to identify a panel of biomarkers and dynamic signature of the disclosure. Predictive algorithms are applied to large datasets to identify correlations between the amount or level of one or more biomarkers detected over time and responsiveness to therapeutic intervention (e.g., ICI monotherapy). In some embodiments, a predictive algorithm comprises performing a statistical test to determine the association of the amount or level of one or more biomarkers detected over time and responsiveness to therapeutic intervention (e.g., ICI monotherapy). In some embodiments, the predictive algorithm is a linear mixed effects model (LMM). In some embodiments, the amount or level of the one or more biomarkers is the dependent variable whereas timepoint, response status and interaction between the two terms are the independent variables. In some embodiments, the significance of the variables are determined with an F-test using Satterthwaite degrees of freedom and type III sum of squares. In some embodiments, biomarkers are analyzed using statistical modeling. Exemplary methods of statistical modeling include, but are not limited to, linear mixed modeling (LMM), analysis of variance (ANOVA), and hierarchical linear modeling (HLM). In some embodiments, biomarkers with altered (e.g., increased or decreased) expression level are analyzed using LMM. In some embodiments, biomarkers with altered (e.g., increased or decreased) expression level are Attorney Docket: AHY-00725 analyzed using ANOVA. In some embodiments, biomarkers with altered (e.g., increased or decreased) expression level are analyzed using HLM. In some embodiments, a statistical modeling method is fit independently to each biomarker, using at least two different time points and their respective biomarkers with altered (e.g., increased or decreased) expression level as inputs. In some embodiments, biomarkers with altered (e.g., increased or decreased) expression level at one or more time points analyzed using statistical modeling generate a model. In some embodiments, a model is assessed for predictive performance. Exemplary measures of predictive performance include, but are not limited to, methods of cross-validation, e.g., k-fold cross-validation (e.g., 5-fold, 10-fold, etc.), leave one out cross-validation (LOOCV), and Monte Carlo, and the like. In some embodiments, a model is assessed for predictive performance using k-fold cross-validation (e.g., 5-fold cross-validation). In some embodiments, a model is assessed using LOOCV. In some embodiments, a model is assessed using Monte Carlo. In some embodiments, a cross-validation method may be repeated any number of times. In some embodiments, a cross-validation method may be repeated about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or about 1000 times. In some embodiments, a cross-validation method may be repeated from about 1 to about 10, about 5 to about 20, about 10 to about 30, about 20 to about 40, about 30 to about 50, about 40 to about 100, about 50 to about 200, about 100 to about 300, about 200 to about 400, about 300 to about 500, about 400 to about 600, about 500 to about 700, about 600 to about 800, about 700 to about 900, about 800 to about 1000, or about 900 to about 1000 times. In some embodiments, a cross-validation method may be repeated about 100 times. In some embodiments, a dynamic signature is determined from comparing biomarker expression level (e.g., increased or decreased) from two or more different time points. In some embodiments, an expression level of two or more biomarkers is obtained from a sample. In some embodiments, a sample is obtained from a subject pre-treatment (e.g., day -1 post-treatment). In some embodiments, a sample is obtained from a subject post-treatment. In some embodiments, a sample is obtained from a subject concurrently with treatment. In some embodiments, post- treatment refers to after initiation of treatment, i.e., after the first administration of a therapeutic to a subject. In some embodiments, a sample is obtained from a subject at time point day -1, 0, 1, 2, 3, 4, 5, 6, or day 7 post-treatment. In some embodiments, a sample is obtained from a subject at time point week 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, Attorney Docket: AHY-00725 or week 24 post-treatment. In some embodiments, a sample is obtained from a subject at time point month 0, 1, 2, 3, 4, 5, or month 6 post-treatment. In some embodiments, a sample is obtained from a subject at time point day -1 post-treatment. In some embodiments, a sample is obtained from a subject at time point week 3 post-treatment. In some embodiments, a sample is obtained from a subject at time point week 6 post-treatment. In some embodiments, a sample is obtained from a subject at time point month 6 post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or biomarker expression levels (e.g., increased or decreased) from two or more different time points. In some embodiments, the two or more time points are selected from: -1, 0, 1, 2, 3, 4, 5, 6, or 7 days post- treatment; 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 weeks post-treatment; and 0, 1, 2, 3, 4, 5, or 6 months post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are selected from day 1, 0, 1, 2, 3, 4, 5, 6, or 7 days post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 weeks post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are selected from 0, 1, 2, 3, 4, 5, or 6 months post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are at least baseline and 3-weeks post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are at least baseline and 6-weeks post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are at least baseline and 6- months post-treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are at least baseline, 3-weeks post-treatment, and 6-months post treatment. In some embodiments, a dynamic signature is obtained by comparing two or Attorney Docket: AHY-00725 more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are at least baseline, 6-weeks post-treatment, and 6-months post treatment. In some embodiments, a dynamic signature is obtained by comparing two or more biomarker expression levels (e.g., increased or decreased) from two or more different time points, wherein the time points are at least baseline and before clinical read out (e.g., before 6- months). In some embodiments, a dynamic signature is identified using computational methods. Without being bound by theory, computational methods may determine whether a defined set of biomarkers show statistically significant and concordant differences between two biological groups, e.g., altered expression of one or more biomarkers between two or more time points. Exemplary computational methods include, but are not limited to, gene set enrichment analysis (GSEA), gene ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, and the like. In some embodiments, a dynamic signature is assessed using GSEA. In some embodiments, a dynamic signature is assessed using GO analysis. In some embodiments, a dynamic signature is assessed using KEGG analysis. In some embodiments, a dynamic signature is assessed using two or more computational methods. In some embodiments, a dynamic signature is assessed using GSEA, GO analysis, and KEGG analysis. In some embodiments, the biomarkers of a dynamic signature are assessed by GSEA using a GO database and are GO annotated. Without being bound by theory, GO annotation identifies one or more biological domains common among the biomarkers of a dynamic signature from the GO database (http: / / www.geneontology.org). Exemplary annotations include, but are not limited to, molecular function (activity biomarkers of a dynamic signature, e.g., catalysis, transport, receptor), cellular component (where biomarkers of a dynamic signature are active, e.g., compartments, complexes, organelles), and biological process (pathways and larger processes to which the biomarkers of a dynamic signature contribute via their respective activity, e.g., signal transduction, DNA repair, myeloid biology). In some embodiments, a dynamic signature is assessed by GSEA using a GO database and identifies one or more common molecular functions. In some embodiments, a dynamic signature is assessed by GSEA using a GO database and identifies one or more common cellular components. In some embodiments, a dynamic signature is assessed by GSEA using a GO database and identifies one or more common biological processes. In some embodiments, a dynamic signature is assessed by GSEA Attorney Docket: AHY-00725 using a GO database and identifies one or more common molecular functions, cellular components, and biological processes, and combinations thereof. In some embodiments, GSEA using a GO database annotates one biological process, e.g., a gene ontology biological process (GOBP). In some embodiments, GSEA using a GO database annotates two or more biological processes. In some embodiments, GSEA using a GO database annotates a dynamic signature and identifies myeloid biology. In some embodiments, a biological process comprises myeloid biology. Exemplary biological process components include, but are not limited to, regulation of macrophage activation, positive regulation of macrophage activation, macrophage activation, and myeloid leukocyte activation. In some embodiments, a biological process component is regulation of macrophage activation. In some embodiments, a biological process component is positive regulation of macrophage activation. In some embodiments, a biological process component is macrophage activation. In some embodiments, a biological process component is myeloid leukocyte activation. In some embodiments, GSEA using a GO database annotates a dynamic signature and identifies myeloid biology, i.e., is a dynamic myeloid signature. Diagnostic Accuracy of Dynamic Signatures Diagnostic accuracy of the methods or kits useful for predicting responsiveness to a therapeutic intervention (e.g., ICI monotherapy) in a subject with cancer can be determined by analyzing the Area Under the Curve (AUC) derived from Receiver Operator Characteristic (ROC) curves. ROC curves are graphical plots that illustrate the ability of a binary classifier system as its discrimination threshold is varied. ROC curves are plotted with true positive rate against the false positive rate, with true positive rate on the y-axis and false positive rate on the x-axis. The true positive rate, also referred to as the sensitivity, is calculated by dividing the number of true positives by the sum of true positives and false negatives. The false positive rate is calculated by either (1) dividing the number of false positives by the sum of true negatives and false positives, or (2) subtracting the specificity from one, wherein specificity is calculated by dividing the number of true negatives by the sum of true negatives and false positives. In some embodiments, ROC curves are generated based on individual amounts of expression of each biomarker. In some embodiments, ROC curves are generated based on a combination of amounts of expression of each biomarker. Attorney Docket: AHY-00725 In some embodiments, the AUC value of the methods or kits described herein is greater than 0.50. In some embodiments, the AUC value of the methods or kits described herein is at least 0.60. In some embodiments, the AUC value of the methods or kits described herein is at least 0.70. In some embodiments, the AUC value of the methods or kits described herein is at least 0.71. In some embodiments, the AUC value of the methods or kits described herein is at least 0.72. In some embodiments, the AUC value of the methods or kits described herein is at least 0.73. In some embodiments, the AUC value the methods or kits described herein is at least 0.74. In some embodiments, the AUC value of the methods or kits described herein is at least 0.75. In some embodiments, the AUC value of the methods or kits described herein is at least 0.76. In some embodiments, the AUC value of the methods or kits described herein is at least 0.77. In some embodiments, the AUC value of the methods or kits described herein is at least 0.78. In some embodiments, the AUC value of the methods or kits described herein is at least 0.79. In some embodiments, the AUC value of the methods or kits described herein is at least 0.80. In some embodiments, the AUC value of the methods or kits described herein is at least 0.81. In some embodiments, the AUC value of the methods or kits described herein is at least 0.82. In some embodiments, the AUC value of the methods or kits described herein is at least 0.83. In some embodiments, the AUC value of the methods or kits described herein is at least 0.84. In some embodiments, the AUC value of the methods or kits described herein is at least 0.85. In some embodiments, the AUC value of the methods or kits described herein is at least 0.86. In some embodiments, the AUC value of the methods or kits described herein is at least 0.87. In some embodiments, the AUC value of the methods or kits described herein is at least 0.88. In some embodiments, the AUC value of the methods or kits described herein is at least 0.89. In some embodiments, the AUC value of the methods or kits described herein is at least 0.90. Diagnostic accuracy of the amount of expression of an individual biomarker or combination of amounts of expression of specific biomarkers can be maximized by implementing a cut-off analysis that takes into account the sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) necessary for clinical utility. Results of amounts of expression are analyzed in any of a variety of ways. In some embodiments, the results are analyzed using a univariate, or single-variable analysis (SV). In some embodiments, the results are analyzed using multivariate analysis (MV). Attorney Docket: AHY-00725 The generation of ROC curves and analysis of a population of samples can be used to establish the cutoff value used to distinguish between different subject sub-groups. For example, the cutoff value can be used to distinguish between a high likelihood of responding to a therapeutic intervention (e.g., ICI monotherapy) and a low likelihood of responding to a therapeutic intervention (e.g., ICI monotherapy). In some embodiments, the cutoff value can distinguish between these subjects. In some embodiments, the methods or kits described herein provide a score indicating the likelihood that a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.70. In some embodiments, the methods or kits described herein provide a score indicating the likelihood that a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.75. In some embodiments, the methods or kits described herein provide a score indicating the likelihood that a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.80. In some embodiments, the methods or kits described herein provide a score indicating the likelihood that a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.85. In some embodiments, the methods or kits described herein provide a score indicating the likelihood that a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.90. In some embodiments, the methods or kits described herein provide a score indicating a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.70. In some embodiments, the methods or kits described herein provide a score indicating a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.75. In some embodiments, the methods or kits described herein provide a score indicating a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.80. In some embodiments, the methods or kits described herein provide a score indicating a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.85. In some embodiments, the methods or kits described herein provide a score indicating a subject with cancer will not respond to ICI monotherapy with a diagnostic accuracy of at least 0.90. Exemplary Non-Responder Dynamic Signatures In some embodiments, a dynamic signature of the disclosure comprises detecting a panel of biomarkers disclosed herein at two or more time points in a subject having cancer that has Attorney Docket: AHY-00725 received an ICI monotherapy. In some embodiments, a dynamic signature of the disclosure comprises detecting a panel of biomarkers disclosed herein before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. Attorney Docket: AHY-00725 In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, at two or more time points in a subject having cancer that has received an ICI monotherapy. Attorney Docket: AHY-00725 In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. Attorney Docket: AHY-00725 In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. Attorney Docket: AHY-00725 In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, at two or more time points in a subject having cancer that has received an ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. Attorney Docket: AHY-00725 In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising at least six biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic signature comprises detecting a panel of biomarkers comprising ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, before a subject having cancer has received an ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. Exemplary Dynamic Myeloid Signatures In some embodiments, a dynamic myeloid signature of the disclosure comprises detecting a panel of biomarkers disclosed herein at two or more time points in a subject having cancer that is non-responsive to ICI monotherapy. In some embodiments, a dynamic myeloid signature of the disclosure comprises detecting a panel of biomarkers disclosed herein at two or more time points in a subject having cancer that is predicted to not likely respond to ICI monotherapy. In some embodiments, a dynamic myeloid signature of the disclosure comprises detecting a panel of biomarkers disclosed herein before a subject is administered ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, at two or more time points in a subject having cancer that is non-responsive to ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and Attorney Docket: AHY-00725 MMP8, at two or more time points in a subject having cancer that is predicted to likely not respond to ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, at two or more time points in a subject having cancer that is non-responsive to ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, at two or more time points in a subject having cancer that is predicted to likely not respond to ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, at two or more time points in a subject having cancer that is non-responsive to ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, at two or more time points in a subject having cancer that is predicted to likely not respond to ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, before a subject is administered ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, before a subject is administered ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. In some embodiments, the dynamic myeloid signature comprises detecting a panel of biomarkers comprising one or more biomarkers selected from: LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, before a Attorney Docket: AHY-00725 subject is administered ICI monotherapy, and at one or more time points from about 3 weeks to about 6 months after administration of the ICI monotherapy. Methods of Use In some aspects, the present disclosure provides methods for identifying the panel of biomarkers and / or dynamic signatures in a subject having cancer that has received an ICI monotherapy. In some embodiments, the panel of biomarkers and / or dynamic signatures described herein predict whether a subject will respond to ICI monotherapy. In some embodiments, the panel of biomarkers and / or dynamic signatures described herein predict a patient is not likely to respond to ICI monotherapy. In some aspects, the present disclosure provides methods for identifying the panel of biomarkers and / or dynamic myeloid signatures in a subject having cancer identified or predicted as non-responsive to ICI monotherapy. In some embodiments, the panel of biomarkers and / or dynamic myeloid signatures described herein predict whether a subject will respond to a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint and an ICI. In some embodiments, the panel of biomarkers and / or dynamic myeloid signatures described herein predict if a patient is likely to respond to a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint and an ICI. In some embodiments, the present disclosure provides methods for administering additional cancer therapeutics to a subject identified or predicted as non-responsive to ICI monotherapy. In some embodiments, the additional cancer therapeutic is a therapeutic targeting a myeloid immune suppressive checkpoint. In some embodiments, the additional cancer therapeutic is a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint and the ICI. In some embodiments, the additional cancer therapeutic is administered as monotherapy, i.e., without the ICI therapy. In some embodiments, an ICI monotherapy is an antibody. In some embodiments, an antibody is specific to PD1 (e.g., anti-PD1), PDL1 (e.g., anti-PDL1), LAG3 (e.g., anti-LAG3), or CTLA4 (e.g., anti-CTLA4). In some embodiments, a subject with cancer is administered an anti- PD1 antibody. In some embodiments, a subject with cancer is administered an anti-PDL1 antibody. In some embodiments, a subject with cancer is administered an anti-LAG3 antibody. In some embodiments, a subject with cancer is administered an anti-CTLA4 antibody. In some Attorney Docket: AHY-00725 embodiments, a subject with cancer is administered one or more of an anti-PD1 antibody, an anti-PDL1 antibody, an anti-LAG3 antibody, and an anti-CTLA4 antibody. Exemplary antibodies include, but are not limited to, ipilimumab, nivolumab, relatlimab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, and dostarlimab. In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint is an anti-cancer therapeutic, e.g., an immunotherapeutic or chemotherapeutic. In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint is an immunotherapeutic (e.g., an antibody). In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint is a chemotherapeutic (e.g., a small molecule). In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint targets a myeloid cell. Exemplary myeloid cells include, but are not limited to myeloid progenitor cells, basophils, neutrophils, eosinophils, monocytes, macrophages, erythrocytes, and platelets. In some embodiments, a subject with cancer identified or predicted as non-responsive to ICI monotherapy is administered a myeloid cell-targeting antibody. In some embodiments, a subject with cancer identified or predicted as non-responsive to ICI monotherapy is administered a myeloid cell-targeting small molecule. Exemplary therapeutics targeting a myeloid immune suppressive checkpoint include, but are not limited to, acalabrutinib, alemtuzumab, arsenic trioxide, asciminib hydrochloride, asparaginase erwinia chrysanthemi, asparaginase erwinia chrysanthemi (recombinant)-rywn, azacitidine, bendamustine hydrochloride, blinatumomab, bortezomib, bosutinib, busulfan, calaspargase pegol-mknl, carfilzomib, carmustine, chlorambucil, ciltacabtagene autoleucel, cladribine, clofarabine, cyclophosphamide, cytarabine, daratumumab, daratumumab and hyaluronidase-fihj, dasatinib, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, doxorubicin hydrochloride liposome, duvelisib, elotuzumab, enasidenib mesylate, fludarabine phosphate, gemtuzumab ozogamicin, gilteritinib fumarate, glasdegib maleate, hydroxyurea, ibrutinib, idarubicin hydrochloride, idecabtagene vicleucel, idelalisib, imatinib mesylate, inotuzumab ozogamicin, isatuximab-irfc, ivosidenib, ixazomib citrate, lenalidomide, melphalan, melphalan hydrochloride, mercaptopurine, methotrexate sodium, midostaurin, mitoxantrone hydrochloride, moxetumomab pasudotox-tdfk, nelarabine, nilotinib, obinutuzumab, ofatumumab, olutasidenib, omacetaxine mepesuccinate, pamidronate disodium, pegaspargase, pemigatinib, plerixafor, pomalidomide, ponatinib hydrochloride, prednisone, recombinant interferon alfa-2b, rituximab, selinexor, tagraxofusp- Attorney Docket: AHY-00725 erzs, teclistamab-cqyv, thalidomide, thioguanine, tisagenlecleucel, venetoclax, vincristine sulfate, zanubrutinib, and zoledronic acid, and combinations thereof. In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint is gene specific, e.g., targets a specific nucleic acid or protein. In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint targets a specific nucleic acid. In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint targets a specific protein. In some embodiments, the therapeutic targeting a myeloid immune suppressive checkpoint targets a biomarker disclosed herein. In some embodiments, the therapeutic targeting a myeloid immune suppressive checkpoint targets one or more biomarkers selected from: LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8. In some embodiments, the therapeutic targets LAIR1. In some embodiments, the therapeutic targets AZU1. In some embodiments, the therapeutic targets CCL3. In some embodiments, the therapeutic targets CST7. In some embodiments, the therapeutic targets HAVCR2. In some embodiments, the therapeutic targets IFNG. In some embodiments, the therapeutic targets IL10. In some embodiments, the therapeutic targets IL1RL1. In some embodiments, the therapeutic targets IL4R. In some embodiments, the therapeutic targets IL6. In some embodiments, the therapeutic targets LBP. In some embodiments, the therapeutic targets MIF. In some embodiments, the therapeutic targets MMP8. In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint is an antibody. In some embodiments, the antibody targets LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, or MMP8. In some embodiments, the antibody targets LAIR1 (e.g., anti- LAIR1). In some embodiments, the antibody targets AZU1 (e.g., anti-AZU1). In some embodiments, the antibody targets CCL3 (e.g., anti-CCL3). In some embodiments, the antibody targets CST7 (e.g., anti-CST7). In some embodiments, the antibody targets HAVCR2 (e.g., anti-HAVCR2). In some embodiments, the antibody targets IFNG (e.g., anti-IFNG). In some embodiments, the antibody targets IL10 (e.g., anti-IL10). In some embodiments, the antibody targets IL1RL1 (e.g., anti-IL1RL1). In some embodiments, the antibody targets IL4R (e.g., anti-IL4R). In some embodiments, the antibody targets IL6 (e.g., anti-IL6). In some embodiments, the antibody targets LBP (e.g., anti-LBP). In some embodiments, the antibody targets MIF (e.g., anti-MIF). In some embodiments, the antibody targets MMP8 (e.g., anti-MMP8). Methods for generating antibodies are known to those of skill in the art. Attorney Docket: AHY-00725 In some embodiments, a therapeutic targeting a myeloid immune suppressive checkpoint is a protein or fragment thereof. In some embodiments, the protein or fragment thereof comprises a wild-type or non-mutated amino acid sequence. In some embodiments, the protein or fragment thereof comprises a recombinant or mutated amino acid sequence. Exemplary proteins or fragments thereof include, but are not limited to, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, thrombolytics, and cytokines. In some embodiments, the protein or fragment thereof is an anticoagulant. In some embodiments, the protein or fragment thereof is a blood factor. In some embodiments, the protein or fragment thereof is a bone morphogenetic protein. In some embodiments, the protein or fragment thereof is an engineered protein scaffold. In some embodiments, the protein or fragment thereof is an enzyme. In some embodiments, the protein or fragment thereof is a growth factor. In some embodiments, the protein or fragment thereof is a hormone. In some embodiments, the protein or fragment thereof is an interferon. In some embodiments, the protein or fragment thereof is an interleukin. In some embodiments, the protein or fragment thereof is a thrombolytic. In some embodiments, the protein or fragment thereof is a cytokine. In some embodiments, the protein or fragment thereof is LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, or MMP8. In some embodiments, the protein or fragment thereof is LAIR1. In some embodiments, the protein or fragment thereof is AZU1. In some embodiments, the protein or fragment thereof is CCL3. In some embodiments, the protein or fragment thereof is CST7. In some embodiments, the protein or fragment thereof is HAVCR2. In some embodiments, the protein or fragment thereof is IFNG. In some embodiments, the protein or fragment thereof is IL10. In some embodiments, the protein or fragment thereof is IL1RL1. In some embodiments, the protein or fragment thereof is IL4R. In some embodiments, the protein or fragment thereof is IL6. In some embodiments, the protein or fragment thereof is LBP. In some embodiments, the protein or fragment thereof is MIF. In some embodiments, the protein or fragment thereof is MMP8. Methods for generating protein or fragment thereof are known to those of skill in the art. As used herein, the terms “subject” and “patient” can be used interchangeably. As used herein, a subject can be a mammal such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats, etc.) or a primate (e.g., monkey and human). In some embodiments, the subject is a human. In some embodiments, a patient to be treated or tested for responsiveness to a treatment Attorney Docket: AHY-00725 according to the methods described herein is one who has been diagnosed with a cancer, such as any cancer described herein. Diagnosis may be performed by any method or technique known in the art, such as x-ray, MRI, or biopsy, and may also be confirmed by a physician. To minimize exposure of a patient to drug treatments that may not be therapeutic, the patient may be determined to be either responsive or non-responsive to a cancer treatment, such as a myeloid suppressive therapeutic agent described herein, according to the methods described herein prior to treatment. As used herein, the terms "treat," "treating" and "treatment" refer to an action that occurs while the subject has a disease, disorder or condition described herein. "Treat," "treatment" and "treating" also refer to the reduction or amelioration of the progression, severity, and / or duration of a disease, disorder or condition described herein resulting from the administration of one or more therapeutic agents described herein. As used herein, the terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. In some embodiments, the subject has a hematological cancer. Hematological cancer as used herein refers to blood-borne tumors (e.g., multiple myeloma, lymphoma and leukemia). In some embodiments, the subject has a solid tumor. "Tumor" and "solid tumor" as used herein, refer to all lesions and neoplastic cell growth and proliferation, whether malignant or benign, and all pre- cancerous and cancerous cells and tissues. "Neoplastic," as used herein, refers to any form of dysregulated or unregulated cell growth, whether malignant or benign, resulting in abnormal tissue growth. Thus, "neoplastic cells" include malignant and benign cells having dysregulated or unregulated cell growth. In some embodiments, the subject has a solid tumor. In some embodiments, the solid tumor is a sarcoma (e.g., a solid tumor comprising closely packed cells embedded in a fibrillar or homogeneous substance). Exemplary sarcomas for treatment, prevention, and / or management using the compositions and methods described herein include chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Attorney Docket: AHY-00725 Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, and telangiectaltic sarcoma. In some embodiments, the solid tumor is a carcinoma (e.g., a malignant growth comprising epithelial cells that have infiltrated surrounding tissues). Exemplary carcinomas for treatment, prevention, and / or management using the compositions and methods described herein include, adenocarcimonas, colorectal carcinoma, colorectal adenocarcinoma, acinar carcinoma, lung carcinoma, alveolar cell carcinoma, basal cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, chorionic carcinoma, colloid carcinoma, corpus carcinoma, cribriform carcinoma, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lymphoepithelial carcinoma, nasopharyngeal carcinoma, papillary carcinoma, renal cell carcinoma of kidney, scirrhous carcinoma, small-cell carcinoma, spheroidal cell carcinoma, squamous carcinoma, squamous cell carcinoma, carcinoma telangiectaticum, and verrucous carcinoma. In some embodiments, the solid tumor is oral, lung, gastrointestinal, genitourinary, liver, bone, nervous system, gynecological, skin, thyroid gland, or adrenal gland. In some embodiments, the solid tumor is oral (buccal cavity, lip, tongue, mouth, pharynx); cardiac (sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma); lung (bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma); gastrointestinal (esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal, rectum); genitourinary tract (kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, Attorney Docket: AHY-00725 transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); liver (hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages); bone (osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors); nervous system (skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); gynecological (uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, Sertoli- Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; hematologic (blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma] hairy cell, lymphoid disorders); skin (malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis), thyroid gland (papillary thyroid carcinoma, follicular thyroid carcinoma, undifferentiated thyroid cancer, medullary thyroid carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma); and adrenal glands (neuroblastoma). In some embodiments, the subject has a myeloproliferative disorder (e.g., blood cancer). The term “myeloproliferative disorders” includes disorders such as polycythemia vera, thrombocythemia, myeloid metaplasia with myelofibrosis, hypereosinophilic syndrome, juvenile Attorney Docket: AHY-00725 myelomonocytic leukemia, systemic mast cell disease, and hematopoietic disorders, in particular, acute-myelogenous leukemia (AML), chronic-myelogenous leukemia (CML), acute- promyelocytic leukemia (APL), and acute lymphocytic leukemia (ALL). Methods of Identifying Dynamic Signatures and Predicting Non-Response In some embodiments, the present disclosure provides methods for identifying dynamic signatures in a subject having cancer and administered an ICI monotherapy. In some embodiments, the present disclosure provides methods for identifying a subject having cancer as not likely to respond to ICI monotherapy. In some embodiments, the subject has received an ICI monotherapy and the dynamic signature predicts the subject is not likely to respond to the ICI monotherapy before clinical readout. In some embodiments, the present disclosure provides methods for predicting whether a subject having cancer and receiving ICI monotherapy will respond to the ICI monotherapy, comprising determining the amount or level of a panel of biomarkers disclosed herein at two or more time points. In some embodiments, the amount or level of the panel of biomarkers is altered (e.g., increased or decreased) between the two or more time points (e.g., between baseline and at least one time point after administration of the ICI monotherapy). In some embodiments, the amount or level of the panel of biomarkers is increased between the two or more time points (e.g., between baseline and at least one time point after administration of the ICI monotherapy). In some embodiments, the increase in the amount or level of the panel of biomarkers between the two or more time points is statistically significant. In some embodiments, the amount or level of the panel of biomarkers is decreased between the two or more time points (e.g., between baseline and at least one time point after administration of the ICI monotherapy). In some embodiments, the decrease in the amount or level of the panel of biomarkers between the two or more time points is statistically significant. In some embodiments, the amount or level of the panel of biomarkers is altered relative to a reference sample. In some embodiments, the amount or level of the panel of biomarkers is increased relative to a reference sample. In some embodiments, the amount or level of the panel of biomarkers is decreased relative to a reference sample. In some embodiments, the increase or decrease of the amount or level of the panel of biomarkers indicates the subject is not likely to respond to the therapeutic intervention (e.g., ICI monotherapy). Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more cancer treatments, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject at two or more different time points, wherein the first time point is prior to administration of the one or more cancer treatments, and the second time point is from about 3 weeks to about 6 months after administration of one or more cancer treatments, wherein the panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more cancer treatments. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more cancer treatments, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more cancer treatments, and the second time point is from about 3 weeks to about 6 months after administration of one or more cancer treatments, wherein the panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non- response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more cancer treatments. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more cancer treatments, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more cancer treatments, and the second time point is from about 3 weeks to about 6 months after administration of one or more cancer treatments, wherein the panel of biomarkers comprises one Attorney Docket: AHY-00725 or more of ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more cancer treatments. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more cancer treatments, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more cancer treatments, and the second time point is from about 3 weeks to about 6 months after administration of one or more cancer treatments, wherein the panel of biomarkers comprises one or more of AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more cancer treatments. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more cancer treatments, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more cancer treatments, and the second time point is from about 3 weeks to about 6 months after administration of one or more cancer treatments, wherein the panel of biomarkers comprises one or more of ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, Attorney Docket: AHY-00725 wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more cancer treatments. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more immune checkpoint inhibitor monotherapies, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject at two or more different time points, wherein the first time point is prior to administration of the one or more immune checkpoint inhibitor monotherapies, and the second time point is from about 3 weeks to about 6 months after administration of the one or more immune checkpoint inhibitor monotherapies, wherein the panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more immune checkpoint inhibitor monotherapies. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more immune checkpoint inhibitor monotherapies, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more immune checkpoint inhibitor monotherapies, and the second time point is from about 3 weeks to about 6 months after administration of the one or more immune checkpoint inhibitor monotherapies, wherein the panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non- response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more immune checkpoint inhibitor monotherapies. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more immune checkpoint inhibitor monotherapies, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more immune checkpoint inhibitor monotherapies, and the second time point is from about 3 weeks to about 6 months after administration of the one or more immune checkpoint inhibitor monotherapies, wherein the panel of biomarkers comprises one or more of ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more immune checkpoint inhibitor monotherapies. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more immune checkpoint inhibitor monotherapies, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the one or more immune checkpoint inhibitor monotherapies, and the second time point is from about 3 weeks to about 6 months after administration of the one or more immune checkpoint inhibitor monotherapies, wherein the panel of biomarkers comprises one or more of AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more immune checkpoint inhibitor monotherapies. In some embodiments, the disclosure provides methods to identify a subject with cancer likely not to respond to one or more immune checkpoint inhibitor monotherapies, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the Attorney Docket: AHY-00725 subject from two or more different time points, wherein the first time point is prior to administration of the one or more immune checkpoint inhibitor monotherapies, and the second time point is from about 3 weeks to about 6 months after administration of the one or more immune checkpoint inhibitor monotherapies, wherein the panel of biomarkers comprises one or more of ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is unlikely to respond to the one or more immune checkpoint inhibitor monotherapies. In some or any of the foregoing embodiments, the one or more immune checkpoint inhibitor monotherapies are selected from an anti-PD1, anti-PDL1, anti-LAG3, and anti-CTLA4 antibodies. Methods of Identifying Subjects for Myeloid Suppressive Therapy In some embodiments, the present disclosure provides methods for identifying dynamic myeloid signatures in a subject having cancer identified or predicted as non-responsive to ICI monotherapy. In some embodiments, the subject is non-responsive to ICI monotherapy and the dynamic myeloid signature identifies the subject as likely to respond to a a therapeutic targeting a myeloid immune suppressive checkpoint. In some embodiments, the subject is non-responsive to ICI monotherapy and the dynamic myeloid signature identifies the subject as likely to respond to a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint and the ICI. In some embodiments, the present disclosure provides methods for predicting whether the subject having cancer identified or predicted as non-responsive to ICI monotherapy will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising determining the amount or level of a panel of biomarkers disclosed herein at two or more time points. In some embodiments, the present disclosure provides methods for predicting whether the subject having cancer identified or predicted as non-responsive to ICI monotherapy will respond to a combination therapy of a therapeutic targeting a myeloid immune suppressive checkpoint and the Attorney Docket: AHY-00725 ICI, comprising determining the amount or level of a panel of biomarkers disclosed herein at two or more time points. In some embodiments, the amount or level of the panel of biomarkers is altered (e.g., increased or decreased) between the two or more time points (e.g., between baseline and at least one time point after administration of the ICI monotherapy). In some embodiments, the increase in the amount or level of the panel of biomarkers between the two or more time points are compared. In some embodiments, the amount or level of the panel of biomarkers is increased between the two or more time points (e.g., between baseline and at least one time point after administration of the ICI monotherapy). In some embodiments, the amount or level of the panel of biomarkers is decreased between the two or more time points (e.g., between baseline and at least one time point after administration of the ICI monotherapy). In some embodiments, the increase in the amount or level of the panel of biomarkers between the two or more time points are compared, thereby producing a response score. In some embodiments, the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint. In some embodiments, the response score correlates with the subject’s likelihood of responding to a combination therapy of the therapeutic targeting a myeloid immune suppressive checkpoint and the ICI. In some embodiments, the amount or level of the panel of biomarkers is altered relative to a reference sample. In some embodiments, the amount or level of the panel of biomarkers is increased relative to a reference sample. In some embodiments, the amount or level of the panel of biomarkers is decreased relative to a reference sample. In some embodiments, the increase or decrease of the amount or level of the panel of biomarkers indicates the subject is likely to respond to the therapeutic intervention (e.g., a therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI). In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 Attorney Docket: AHY-00725 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel Attorney Docket: AHY-00725 of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response Attorney Docket: AHY-00725 score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and Attorney Docket: AHY-00725 (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score Attorney Docket: AHY-00725 indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: Attorney Docket: AHY-00725 (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, Attorney Docket: AHY-00725 CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response Attorney Docket: AHY-00725 score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the foregoing methods comprise administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score Attorney Docket: AHY-00725 indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 Attorney Docket: AHY-00725 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, Attorney Docket: AHY-00725 CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, Attorney Docket: AHY-00725 PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and Attorney Docket: AHY-00725 (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the Attorney Docket: AHY-00725 second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score Attorney Docket: AHY-00725 indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the foregoing methods comprise administering the therapeutic targeting LAIR1, alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more two different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to a combination therapy of the additional cancer therapeutic and the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicated as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more Attorney Docket: AHY-00725 different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more biomarkers from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicated as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and the second time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more Attorney Docket: AHY-00725 of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more biomarkers from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more biomarkers from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicated as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing an amount or Attorney Docket: AHY-00725 level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more biomarkers from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to Attorney Docket: AHY-00725 determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more biomarkers from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is Attorney Docket: AHY-00725 from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; and (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to a the additional cancer therapeutic, alone or in combination with the ICI; and (iii) administering the additional cancer therapeutic alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI; and (iv) administering the additional cancer Attorney Docket: AHY-00725 therapeutic alone or in combination with the ICI to the subject determined to have the response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicated as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI; and (iv) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone in combination with the ICI to the subject determined to have the response score. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI; and (iii) administering the additional cancer therapeutic alone in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI; and (iv) administering the additional cancer therapeutic alone or in combination with the ICI to the subject determined to have the response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicated as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI Attorney Docket: AHY-00725 monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more biomarkers from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI; and (iv) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have the response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) Attorney Docket: AHY-00725 comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI; and (iii) administering the additional cancer therapeutic alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer that is non-responsive to ICI monotherapy that will respond to an additional cancer therapeutic, comprising: (i) providing a subject identified or predicted as a non-responder or predicted to be a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the additional cancer therapeutic, alone or in combination with the ICI; and (iv) administering the additional cancer therapeutic alone or in combination with the ICI to the subject determined to have the response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicated as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI; and (iii) administering the Attorney Docket: AHY-00725 therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI; and (iv) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have the response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic Attorney Docket: AHY-00725 targeting LAIR1, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iv) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have the response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to identify a subject with cancer identified or predicted as non-responsive to ICI monotherapy that will respond to a therapeutic targeting LAIR1, comprising: (i) providing a subject identified or predicted as a non-responder to an ICI monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the ICI monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the ICI monotherapy, wherein the Attorney Docket: AHY-00725 panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates with the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iv) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have the response score. Methods of Treating Cancer In some embodiments, the disclosure provides a method of treating cancer in a subject, comprising identifying the subject as not likely to respond to ICI monotherapy based on a dynamic signature disclosed herein, and administering at least one additional cancer therapeutic to the subject. In some embodiments, the disclosure provides a method of treating cancer in a subject identified or predicted as non-responsive to ICI monotherapy, comprising identifying the subject as likely to respond to an additional cancer therapeutic (e.g., a therapeutic targeting a myeloid immune suppressive checkpoint), alone or in combination with the ICI based on a dynamic myeloid signature disclosed herein, and administering the additional cancer therapeutic (e.g., the therapeutic targeting a myeloid immune suppressive checkpoint), alone or in combination with the ICI monotherapy to the subject. In some embodiments, the additional cancer therapeutic includes but is not limited to surgery, radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and / or systemic radioactive isotopes), chemotherapy, immunotherapy, endocrine therapy, hyperthermia, cryotherapy, transplant (e.g., stem cell or bone marrow), agents to attenuate adverse effects, corticosteroids (e.g., triamcinolone, methylprednisolone, budesonide, dexamethasone, triamcinolone, prednisone, hydrocortisone, dexamethasone, betamethasone, prednisolone, deflazacort, aldosterone, and combinations thereof), or a combination thereof. In some embodiments, the cancer therapeutic is radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and / or systemic radioactive isotopes). In some embodiments, the cancer therapeutic is chemotherapy. In some embodiments, the cancer therapeutic is immunotherapy. In some embodiments, the cancer therapeutic is endocrine therapy. In some Attorney Docket: AHY-00725 embodiments, the cancer therapeutic is hyperthermia. In some embodiments, the cancer therapeutic is cryotherapy. In some embodiments, the cancer therapeutic is a transplant (e.g., stem cell or bone marrow). In some embodiments, the cancer therapeutic is an agent to attenuate adverse effects. Exemplary immunotherapy treatments include, but are not limited to, immune checkpoint inhibitors (ICI; e.g., antibodies), T-cell transfer therapy (e.g., CAR T-cell therapy and TIL therapy), monoclonal antibodies (also known as therapeutic antibodies), cancer treatment vaccines (e.g., tumor cell-derived or dendritic cell-derived, oncolytic virus therapy), immune system modulators (e.g., cytokines, Bacillus Calmette-Guerin (BCG), and immunomodulatory drugs (also known as biological response modifiers). Exemplary cytokines include, but are not limited to, interferons (INFs) and interleukins (ILs). Exemplary immunomodulatory drugs include, but are not limited to, thalidomide, lenalidomide, pomalidomide, and imiquimod. In some embodiments, a subject with cancer is administered one or more ICI therapies (e.g., antibodies). In some embodiments, a subject with cancer is administered T-cell transfer therapy (e.g., CAR T-cell therapy and TIL therapy). In some embodiments, a subject with cancer is administered monoclonal antibodies (also known as therapeutic antibodies). In some embodiments, a subject with cancer is administered cancer treatment vaccines (e.g., tumor cell- derived or dendritic cell-derived, or oncolytic virus therapy). In some embodiments, a subject with cancer is administered immune system modulators (e.g., cytokines, Bacillus Calmette- Guerin (BCG), and immunomodulatory drugs (also known as biological response modifiers)). In some embodiments, a subject with cancer is administered a combination of one or more of ICI monotherapies (e.g., antibodies), T-cell transfer therapy (e.g., CAR T-cell therapy and TIL therapy), monoclonal antibodies (also known as therapeutic antibodies), cancer treatment vaccines (e.g., tumor cell-derived or dendritic cell-derived, oncolytic virus therapy), immune system modulators (e.g., cytokines, Bacillus Calmette-Guerin (BCG), and immunomodulatory drugs (also known as biological response modifiers). In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the Attorney Docket: AHY-00725 first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the Attorney Docket: AHY-00725 first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, Attorney Docket: AHY-00725 MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response Attorney Docket: AHY-00725 score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response Attorney Docket: AHY-00725 score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the Attorney Docket: AHY-00725 second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score Attorney Docket: AHY-00725 indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score Attorney Docket: AHY-00725 indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. Attorney Docket: AHY-00725 In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: Attorney Docket: AHY-00725 (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LILRB4, LAIR1, VSIG4, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the ICI; and (iii) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the Attorney Docket: AHY-00725 first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the Attorney Docket: AHY-00725 first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, Attorney Docket: AHY-00725 MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response Attorney Docket: AHY-00725 score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response Attorney Docket: AHY-00725 score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: Attorney Docket: AHY-00725 (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the Attorney Docket: AHY-00725 second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of the biomarkers selected from: AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates with a diagnostic accuracy (AUC) of at least 0.7 that the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in a biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of LAIR1, AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, and MMP8, and Attorney Docket: AHY-00725 (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the ICI; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the ICI to the subject determined to have a response score. In some embodiments, the disclosure provides methods to treat a subject with cancer, comprising: (i) identifying the subject as likely to not respond to an ICI monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one ...

Claims

Attorney Docket: AHY-00725 CLAIMS 1. A method of providing a therapeutic targeting LAIR1 to treat cancer in the subject, comprising: (i) identifying the subject as likely to not respond to an immune checkpoint inhibitor monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in the biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor, thereby treating cancer in the subject.Attorney Docket: AHY-00725 2. A method for identifying a subject that is non-responsive to an immune checkpoint inhibitor monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) identifying the subject as likely to not respond to an immune checkpoint inhibitor monotherapy administered to the subject, comprising: (a) providing an amount or level of a first panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of an immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the first panel of biomarkers comprises one or more of CA6, CDNF, MIA, MYOC, NEFL, and TCL1B, and (b) comparing the amount or level of the first panel of biomarkers from the two or more different time points to determine a non-response score, wherein the non-response score indicates the subject is not likely to respond to the immune checkpoint inhibitor monotherapy; and (ii) identifying the subject as likely to respond to a therapeutic targeting LAIR1, comprising: (a) providing an amount or level of a second panel of biomarkers in the biological sample obtained from the subject from the two or more different time points, wherein the second panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1, and (b) comparing the amount or level of the second panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor to the subject determined to have a response score.

3. The method of any one of claims 1-2, wherein the immune checkpoint inhibitor monotherapy targets PD-1, PD-L1, CTLA4, LAG3, or any combination thereof.Attorney Docket: AHY-00725 4. The method of any one of claims 1-3, wherein the immune checkpoint inhibitor monotherapy is an antibody.

5. The method of claim 4, wherein the antibody is ipilimumab, nivolumab, relatlimab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, or dostarlimab.

6. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises CA6, CDNF, MIA, MYOC, NEFL, and TCL1B.

7. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises one or more of ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS.

8. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises at least six of ADAM22, ADAMTS8, AMTS8, ANGPT2, AOC1, BCL2L11, BMP4, BRK1, CA6, CCL13, CCL25, CD14, CD34, CDH17, CDNF, CERT, CES3, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FBP1, FRZB, GBP2, GFBP2, GLT8D2, GPR37, HGF, HMBS, IGFBP2, IL5, IL6, ITGB6, ITM2A, KRT5, LILRB4, MIA, MMP13, MMP3, MMP8, MYOC, NEFL, NID1, NOS3, NRP1, PAEP, PAPPA, PRTG, PSPN, PTGDS, SFTPD, SMOC1, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TGREM2, TINAGL1, TNC, TNFRSF10B, TNFSF14, VASN, and WARS.

9. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises one or more of ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN.Attorney Docket: AHY-00725 10. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises at least six of ADAM22, BMP4, CA6, CCL25, CDH17, CDNF, CES3, GBP2, HGF, HMBS, IL5, IL6, ITGB6, KRT5, MIA, MMP13, MMP3, MYOC, NEFL, NID1, NRP1, PAEP, PTGDS, SFTPD, SMOC1, TCL1B, TGREM2, TNC, TNFRSF10B, TNFSF14, and VASN.

11. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises one or more of AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS.

12. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises at least six of AMTS8, ANGPT2, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CERT, CLEC4A, CPVL, CSF3, CTSF, CTSL, DKK4, ECE1, ENG, FRZB, GFBP2, GLT8D2, ITGB6, LILRB4, MIA, MMP8, MYOC, NEFL, PAEP, PAPPA, PRTG, PSPN, TCL1A, TCL1B, TCN2, TDGF1, TFPI, TINAGL1, and WARS.

13. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises one or more of ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS.

14. The method of any one of claims 1-5, wherein the first panel of biomarkers comprises at least six of ADAMTS8, ANGPT2, AOC1, BCL2L11, BRK1, CA6, CCL13, CD14, CD34, CDNF, CLEC4A, CPVL, DKK4, ECE1, FBP1, GPR37, IGFBP2, ITM2A, LILRB4, MIA, MMP13, MMP8, MYOC, NEFL, NOS3, PAPPA, PSPN, TCL1A, TCL1B, TCN2, TFPI, TINAGL1, VASN, and WARS.

15. The method of any one of claims 1-14, wherein the second panel of biomarkers comprises at least four of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1.Attorney Docket: AHY-00725 16. The method of any one of claims 1-14, wherein the second panel of biomarkers comprises 2-13 biomarkers of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1.

17. The method of any one of claims 1-14, wherein the second panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1.

18. The method of any one of claims 1-17, wherein the second panel of biomarkers further comprises LILRB4 and VSIG4.

19. The method of any one of claims 1-18, wherein the first panel of biomarkers comprises proteins.

20. The method of claim 19, wherein (i)(a) comprises detecting the first panel of biomarkers in the biological sample by enzyme-linked immunosorbent assay (ELISA) or proximity extension assay (PEA).

21. The method of any one of claims 1-21, wherein the second panel of biomarkers comprises proteins.

22. The method of 21, wherein (ii)(a) comprises detecting the second panel of biomarkers in the biological sample by enzyme-linked immunosorbent assay (ELISA) or proximity extension assay (PEA).

23. The method of any one of claims 1-22, wherein the first panel of biomarkers comprises nucleic acid molecules.

24. The method of claim 23, wherein (i)(a) comprises detecting the first panel of biomarkers in the biological sample by a nucleic acid hybridization assay, a nucleic acid amplification assay, or sequencing.Attorney Docket: AHY-00725 25. The method of any one of claims 1-24, wherein the second panel of biomarkers comprises nucleic acid molecules.

26. The method of 25, wherein (ii)(a) comprises detecting the second panel of biomarkers in the biological sample by a nucleic acid hybridization assay, a nucleic acid amplification assay, or sequencing.

27. The method of any one of claims 1-26, wherein the therapeutic targeting LAIR1 is an antibody, a nucleic acid molecule, a protein therapeutic, a cell therapy, or a small molecule.

28. The method of claim 27, wherein the therapeutic targeting LAIR1 is an antibody.

29. The method of any one of claims 1-28, wherein the biological sample is a blood sample, a serum sample, or a plasma sample.

30. The method of claim 29, wherein the biological sample is a plasma sample.

31. The method of any one of claims 1-30, wherein the at least one subsequent time point is before clinical readout.

32. The method of any one of claims 1-31, wherein the first and second panel of biomarkers is determined from at least two subsequent time points.

33. The method of any one of claims 1-32, wherein the amount or level of the first panel of biomarkers is increased between the first time point and the at least one subsequent time point.

34. The method of claim 33, wherein the increased amount or level of the first panel of biomarkers between the first time point and the at least one subsequent time point is statistically significant.Attorney Docket: AHY-00725 35. The method of any one of claims 1-34, wherein the amount or level of the second panel of biomarkers is increased between the first time point and the at least one subsequent time point.

36. The method of claim 35, wherein the increased amount or level of the first panel of biomarkers between the first time point and the at least one subsequent time point is statistically significant.

37. The method of any one of claims 1-36, wherein the non-response score has a diagnostic accuracy (AUC) of at least 0.7, optionally wherein the diagnostic accuracy is at least 0.

8.

38. The method of any one of claims 1-37, wherein the non-response score indicated the subject will not respond to the immune checkpoint inhibitory therapy.

39. The method of any one of claims 1-38, wherein the therapeutic targeting LAIR1 improves the subject’s response to the immune checkpoint inhibitor monotherapy.

40. A kit suitable for performing the method of any one of claims 1-39, comprising (i) one or more reagents for detecting the amount or level of the first panel of biomarkers, and (ii) instructions for detecting the amount or level of the first panel of biomarkers in a biological sample from a subject obtained from two or more different time points.

41. The kit of claim 40, comprising (iii) one or more reagents for detecting the amount or level of the second panel of biomarkers, and (iv) instructions for detecting the amount or level of the second panel of biomarkers in a biological sample from a subject obtained from two or more different time points.

42. A kit suitable for performing the method of any one of claims 1-39, comprising (i) one or more reagents for detecting the amount or level of the second panel of biomarkers, and (ii) instructions for detecting the amount or level of the second panel of biomarkers in a biological sample from a subject obtained from two or more different time points.Attorney Docket: AHY-00725 43. The kit of claim 42, comprising (iii) one or more reagents for detecting the amount or level of the first panel of biomarkers, and (iv) instructions for detecting the amount or level of the first panel of biomarkers in a biological sample from a subject obtained from two or more different time points.

44. The kit of any one of claims 40-43, comprising instructions for identifying the subject as not likely to respond to an immune checkpoint inhibitor monotherapy.

45. The kit of any one of claims 40-44, comprising instructions for identifying the subject as likely to respond to a combination therapy of a therapeutic targeting LAIR1.

46. The kit of any one of claims 40-45, wherein the biological sample is a blood sample, a serum sample, or a plasma sample.

47. A method for identifying a subject that is non-responsive or predicted to be non- responsive to an immune checkpoint inhibitor monotherapy for administering a therapeutic targeting LAIR1, comprising: (i) providing an amount or level of a panel of biomarkers in a biological sample obtained from the subject at two or more different time points, wherein the first time point is prior to administration of the immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor monotherapy, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1; (ii) comparing the amount or level of the panel of biomarkers from the two or more different time points to determine a response score, wherein the response score indicates the subject’s likelihood of responding to the therapeutic targeting LAIR1, alone or in combination with the immune checkpoint inhibitor monotherapy; and (iii) administering the therapeutic targeting LAIR1 alone or in combination with the immune checkpoint inhibitor to the subject determined to have a response score.Attorney Docket: AHY-00725 48. The method of claim 47, wherein the therapeutic targeting LAIR1 is an antibody, a nucleic acid molecule, a protein therapeutic, a cell therapy, or a small molecule.

49. The method of claim 48, wherein the therapeutic targeting LAIR1 is an antibody.

50. The method of any one of claims 47-49, wherein the panel of biomarkers comprises at least four of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1.

51. The method of any one of claims 47-49, wherein the panel of biomarkers comprises 2-13 biomarkers of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1.

52. The method of any one of claims 47-49, wherein the panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF, MMP8, and LAIR1.

53. The method of any one of claims 47-52, wherein the panel of biomarkers further comprises LILRB4 and VSIG4.

54. A method for identifying a subject for administering a therapeutic targeting a myeloid immune suppressive checkpoint, comprising: (i) providing a subject identified as a non-responder or predicted to be a non-responder to an immune checkpoint inhibitor monotherapy; (ii) determining an amount or level of a panel of biomarkers in a biological sample obtained from the subject from two or more different time points, wherein the first time point is prior to administration of the immune checkpoint inhibitor monotherapy, and at least one subsequent time point is from about 3 weeks to about 6 months after administration of the immune checkpoint inhibitor, wherein the panel of biomarkers comprises one or more of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8; (iii) comparing the amount or level of the one or more proteins from the two or more different time points to determine a response score, wherein the response score correlates withAttorney Docket: AHY-00725 the subject’s likelihood of responding to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the immune checkpoint inhibitor; and (iv) administering the therapeutic targeting a myeloid immune suppressive checkpoint alone or in combination with the immune checkpoint inhibitor to the subject determined to have the response score.

55. The method of claim 54, wherein the panel of biomarkers comprises at least four of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8.

56. The method of claim 54, wherein the panel of biomarkers comprises 2-12 of AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8.

57. The method of claim 54, wherein the panel of biomarkers comprises AZU1, CCL3, CST7, HAVCR2, IFNG, IL10, IL1RL1, IL4R, IL6, LBP, MIF and MMP8.

58. The method of any one of claims 54-57, wherein the panel of biomarkers further comprises at least one of LAIR1, LILRB4 and VSIG4.

59. The method of claim 58, wherein the panel of biomarkers further comprises LAIR1, LILRB4 and VSIG4.

60. The method of any one of claims 54-59, wherein the therapeutic targeting a myeloid immune suppressive checkpoint is an antibody, a nucleic acid molecule, a protein therapeutic, a cell therapy, or a small molecule.

61. The method of any one of claims 47-60, wherein the immune checkpoint inhibitor targets PD-1, PD-L1, CTLA4, LAG3, or any combination thereof.

62. The method of claim 61, wherein the immune checkpoint inhibitor is an antibody.

63. The method of claim 62, wherein the antibody is ipilimumab, nivolumab, relatlimab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, or dostarlimab.Attorney Docket: AHY-00725 64. The method of any one of claims 47-63, wherein the panel of biomarkers comprises proteins.

65. The method of claim 64, wherein determining the amount or level of a panel of biomarkers comprises detecting the panel of biomarkers in the biological sample by enzyme- linked immunosorbent assay (ELISA) or proximity extension assay (PEA).

66. The method of any one of claims 47-65, wherein the panel of biomarkers comprises nucleic acid molecules.

67. The method of claim 66, wherein determining the amount or level of a panel of biomarkers comprises detecting the panel of biomarkers in the biological sample by a nucleic acid hybridization assay, a nucleic acid amplification assay or sequencing.

68. The method of any one of claims 47-67, wherein the biological sample is a blood sample, a serum sample, or a plasma sample.

69. The method of claim 68, wherein the biological sample is a plasma sample.

70. The method of any one of claims 47-69, wherein the at least one subsequent time point is before clinical readout.

71. The method of any one of claims 47-70, wherein the panel of biomarkers is determined from at least two subsequent time points.

72. The method of any one of claims 47-71, wherein the amount or level of the panel of biomarkers is increased between the first time point and the at least one subsequent time point.

73. The method of claim 72, wherein the increased amount or level of the panel of biomarkers between the first time point and the at least one subsequent time point is statistically significant.Attorney Docket: AHY-00725 74. The method of any one of claims 47-73, wherein the response score indicates the subject will respond to the therapeutic targeting a myeloid immune suppressive checkpoint, alone or in combination with the immune checkpoint inhibitor.

75. A kit suitable for performing the method of any one of claims 47-74, comprising (i) one or more reagents for detecting the amount or level of the panel of biomarkers, and (ii) instructions for detecting the amount or level of the panel of biomarkers in a biological sample from a subject obtained from two or more different time points.

76. The kit of claim 75, wherein the instructions comprise steps for identifying the subject as likely to respond to a combination therapy of a therapeutic targeting LAIR1 or a therapeutic targeting a myeloid immune suppressive checkpoint and an immune checkpoint inhibitor.

77. The kit of claim 75 or 76, wherein the biological sample is a blood sample, a serum sample, or a plasma sample.

Images